Massachusetts Drug and Alcohol Outpatient Licensing: BSAS Requirements

Author: A. Ant, CADC-II, Licensing & Accreditation Expert

Apply now: General Suitability Notice of Intent | Questions: bsas-noi-suitability@mass.gov

Massachusetts Drug and Alcohol Outpatient Licensing: BSAS Outpatient Services

Outpatient SUD treatment in Massachusetts runs through 105 CMR 164.200, and BSAS defines the sub-categories more precisely than a lot of operators expect going in, precise enough that guessing which one describes your program is a real risk.

Correction (October 2026): earlier versions of the ketamine and medication sections said every BSAS outpatient program sits on a DPH or DMH clinic or hospital license, and described the medication rule as nondiscriminatory access to opioid use disorder drugs under the 2018 CARE Act. Freestanding programs are licensed by BSAS directly, and the rule is the 105 CMR 164.009(B) attestation described below.

Day Treatment has an actual hour requirement

Day Treatment isn’t a loose label in Massachusetts. It’s defined as an intensive outpatient program providing direct patient services through group, individual, and family SUD counseling for a minimum of 3.5 hours per day, at least three days a week. If your program doesn’t meet that threshold, BSAS isn’t going to consider it Day Treatment regardless of what you call it internally, and that mismatch matters when your marketing describes a level of care your licensed hours don’t support.

Outpatient Withdrawal Treatment Service is its own category

This is ambulatory SUD treatment that clinically manages withdrawal symptoms through medical and ancillary treatment without a 24-hour residential setting. It’s a distinct service type from Day Treatment and from the 24-Hour Diversionary Services covered under inpatient, so don’t assume outpatient withdrawal management and Day Treatment share the same standards just because both happen outside a residential setting.

Opioid Treatment Programs and MAT access

Massachusetts goes further than most states on guaranteed medication access, a detail easy to miss. OTPs fall under Part Two of 105 CMR 164 alongside the other specific service categories, and like any program giving medical care they run it under a Medical Director, whom 105 CMR 164.005 makes responsible for all of the program’s medical services. Every license application also carries two attestations under 105 CMR 164.009(B) that matter whether or not you run a dedicated OTP: the program will provide all FDA-approved medications for addiction treatment, directly or through a qualified service organization agreement, and it will serve Massachusetts residents with public health insurance on a nondiscriminatory basis and report its payer mix quarterly, as M.G.L. c. 111E, § 7 requires. Neither is a narrow OTP-only rule. It reflects the same direction other states are moving in around guaranteed MAT access, and it’s worth building into your program design even if medication management isn’t your primary service line.

Accreditation can count toward compliance

The “Deemed Status” definition in 105 CMR 164.005 reaches outpatient programs too: the Department’s acceptance of accreditation, from an accrediting body the Commissioner has approved, as evidence of compliance with one or more requirements. The regulation stops at the definition. There’s no list of approved accreditors and no list of covered requirements, so get BSAS to confirm what a CARF or Joint Commission survey counts for in your case. You still file the Notice of Intent either way.

Central Registry System participation

If you’re operating an OTP specifically, 105 CMR 164.305 requires participation in the Central Registry System, which verifies medication and dose at admission and keeps a patient from being enrolled in two OTPs at once. It’s an ongoing compliance obligation, not a one-time signup.

Opening a Ketamine Clinic Next to a Massachusetts Outpatient Program

Based on DPH’s January 2024 clinic licensure memo, 105 CMR 140 and 105 CMR 164. Massachusetts hasn’t issued ketamine clinic rules, so confirm the structure with counsel and DPH.

Nothing in Massachusetts law prohibits a stand-alone ketamine clinic, and DPH has spelled out the ownership line more plainly than most states.

Ownership Routes

The first route is a practitioner-owned practice. DPH’s January 3, 2024 memo to licensees says an entity offering ambulatory medical services is subject to clinic licensure under 105 CMR 140 unless it’s wholly owned and controlled by its practitioners and doesn’t use terms like “clinic,” “institute” or “dispensary” in its name. A physician-owned professional corporation that calls itself a ketamine clinic has, by that standard, named itself into a licensure requirement. The second route is a DPH-licensed clinic, which can have lay ownership but must meet 105 CMR 140’s staffing and administrative rules, and The same memo warns that missing those staffing rules can cost the clinic license and send individual providers to their licensing boards, and that an unlicensed entity holding itself out as a clinic can be referred to the Attorney General’s Office over deceptive practices. An MSO contracting with a practitioner-owned practice is the third option, for investors who’d rather keep the practice itself outside clinic licensure.

Next to a BSAS Program

A BSAS outpatient program that operates inside a DPH-licensed clinic, under a BSAS approval, already has a clinic license underneath it, so an operator may be tempted to run ketamine under that same license. That can work in principle, but the ketamine service needs DPH’s sign-off as an addition to the clinic license and has to stay outside the BSAS-approved SUD program. A freestanding program licensed by BSAS alone has no clinic license to extend, which sends it back to the ownership routes above. Separate records, a separately registered ketamine supply and written 42 CFR Part 2 consent before an addiction treatment record moves over keep the two from blurring. Ketamine also doesn’t count toward the medication attestation described above, which covers FDA-approved addiction medications.

How to Submit Your BSAS Notice of Intent

Outpatient programs start with the same General Suitability Notice of Intent process that covers residential and diversionary services, detailed on BSAS’s Information for Initial SUD Program Licensure page. For questions about the suitability and licensing process, BSAS’s contact is bsas-noi-suitability@mass.gov.

See our Massachusetts Behavioral Health Licensing page for the full picture.

This content is provided for general informational purposes only and should not be construed as medical, clinical, legal, financial, tax, accounting, insurance, licensing, accreditation, regulatory, billing, employment, or compliance advice. Requirements change often. Consult qualified professionals for guidance specific to your situation.

Classifying your Massachusetts outpatient program under 164.200? Let’s talk it through.

Sources

• Massachusetts DPH, 105 CMR 164.000 (164.005 definitions of Day Treatment, Outpatient Withdrawal Treatment Service, Deemed Status, Medical Director and Central Registry; 164.009(B) attestations; 164.031): Licensure of Substance Use Disorder Treatment Programs (checked October 8, 2026)
• 105 CMR 164 Part Two, including 164.200 and 164.300 (Cornell LII mirror): Requirements for Service Provision (checked October 8, 2026)
• 105 CMR 164.305 (Cornell LII mirror): Central Registry System participation for Opioid Treatment Programs (checked October 8, 2026)
• Massachusetts DPH: Reminder to Licensees Regarding Licensure Obligations, January 3, 2024 (checked October 8, 2026)
• BSAS: Information for Initial SUD Program Licensure and the General Suitability Notice of Intent (checked October 8, 2026)